Sökning: id:"swepub:oai:DiVA.org:uu-382943" >
The SGLT2 Inhibitor...
The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity : A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients.
-
Latva-Rasku, Aino (författare)
-
Honka, Miikka-Juhani (författare)
-
- Kullberg, Joel, 1979- (författare)
- Uppsala universitet,Radiologi
-
visa fler...
-
Mononen, Nina (författare)
-
Lehtimäki, Terho (författare)
-
Saltevo, Juha (författare)
-
Kirjavainen, Anna K (författare)
-
Saunavaara, Virva (författare)
-
Iozzo, Patricia (författare)
-
Johansson, Lars (författare)
-
Oscarsson, Jan (författare)
-
Hannukainen, Jarna C (författare)
-
Nuutila, Pirjo (författare)
-
visa färre...
-
(creator_code:org_t)
- 2019-03-18
- 2019
- Engelska.
-
Ingår i: Diabetes Care. - : American Diabetes Association. - 0149-5992 .- 1935-5548. ; 42:5, s. 931-937
- Relaterad länk:
-
https://care.diabete...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.2...
-
visa färre...
Abstract
Ämnesord
Stäng
- OBJECTIVE: The aim of this study was to investigate tissue-specific effects of dapagliflozin on insulin sensitivity and liver and body fat in patients with type 2 diabetes.RESEARCH DESIGN AND METHODS: This randomized, double-blind, parallel group, placebo-controlled study recruited 32 patients with type 2 diabetes. Enrolled patients were to have HbA1c 6.5-10.5% (48-91 mmol/mol) and ≥3 months of stable treatment with metformin, dipeptidyl peptidase 4 inhibitor, or their combination. Patients were randomized 1:1 to receive 10 mg dapagliflozin or placebo daily for 8 weeks. Before and after the intervention, tissue insulin sensitivity was measured using [18F]-fluorodeoxyglucose and positron emission tomography during hyperinsulinemic-euglycemic clamp. Liver proton density fat fraction (PDFF) and adipose tissue volumes were assessed using MRI, and blood biomarkers were analyzed.RESULTS: After 8 weeks, glycemic control was improved by dapagliflozin (placebo-corrected change in HbA1c -0.39%, P < 0.01), but whole-body glucose uptake was not increased (P = 0.90). Tissue-specific insulin-stimulated glucose uptake did not change in skeletal muscle, liver, myocardium, or white and brown adipose tissue, and endogenous glucose production remained unaffected. However, there were significant placebo-corrected decreases in liver PDFF (-3.74%, P < 0.01), liver volume (-0.10 L, P < 0.05), visceral adipose tissue volume (-0.35 L, P < 0.01), interleukin-6 (-1.87 pg/mL, P < 0.05), and N-terminal prohormone of brain natriuretic peptide (-96 ng/L, P = 0.03).CONCLUSIONS: In this study, 8 weeks of treatment with dapagliflozin reduced liver PDFF and the volume of visceral adipose tissue in obese patients with type 2 diabetes. Although glycemic control was improved, no effect on tissue-level insulin sensitivity was observed.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Latva-Rasku, Ain ...
-
Honka, Miikka-Ju ...
-
Kullberg, Joel, ...
-
Mononen, Nina
-
Lehtimäki, Terho
-
Saltevo, Juha
-
visa fler...
-
Kirjavainen, Ann ...
-
Saunavaara, Virv ...
-
Iozzo, Patricia
-
Johansson, Lars
-
Oscarsson, Jan
-
Hannukainen, Jar ...
-
Nuutila, Pirjo
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Endokrinologi oc ...
- Artiklar i publikationen
-
Diabetes Care
- Av lärosätet
-
Uppsala universitet